Comparison of the Clinical Result of Diverse β-Blockers in Heart Failure Patients: A Systematic Review

Background: Starting from the mid-late 90s, β-blockers have ended up as the therapy of choice for heart failure (HF). β-blockers act with important and reliable beneficial effects on survival and reduction of the manifestations of patients with heart failure (HF). In a placebo-controlled study conducted at that time, β--blockers have been recognized as necessary treatment in patients who are slowly but steadily. However, today there are many options for β-blockers. Objective: To provide a logical basis for the use of β-blockers for patients with heart failure and determine the most effective β-blockers. Methods: The authors made statistical associations, and calculated the different levels and risks that can distribute different blockers in heart failure patients. Studies were identified from Scopus, Science Direct, PubMed, and Google Scholar databases and then analyzed using Prism Chart 2020. Results: Carvedilol is a superior drug class against cardiac remodeling and consequent heart failure compared to other specific β-blockers. Some of its advantages include combining comprehensive blocking of all 3 adrenergic receptors, anti-apoptotic and anti-endothelin effects. Conclusions: Carvedilol is said to be the most effective heart drug to date, although many other side effects have been discovered. There needs to be a breakthrough in halal medicine for halal medicinal diseases when used by the Muslim community, which is relatively safer and more comfortable to use